Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : UBS Adjusts Eli Lilly's Price Target to $193 From $170, Modeling Higher Probability of Success for Donanemab; Neutral Rating Kept

05/10/2021 | 10:56am EDT


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
07/23ELI LILLY AND : (LLY) sees Significant Insider Selling Continuing
MT
07/23A Guiding Light For The Research Safe Harbor And "Research Tools"?
AQ
07/22ELI LILLY AND : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
07/22INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at Eli Lilly
MT
07/22ELI LILLY AND : Lilly Confirms Date and Conference Call for Second-Quarter 2021 ..
PR
07/21INSIDER TRENDS : Selling By Insiders Continues at Eli Lilly
MT
07/19TALKSPACE : Hires Jennifer Fulk as CFO
MT
07/16ELI LILLY AND : Insider Selling in Eli Lilly (LLY) Shares Continues
MT
07/16Health Care Climbs On Defensive Bias -- Health Care Roundup
DJ
07/16ELI LILLY AND : Incyte Say FDA May Miss Target Action Data for Baricitinib
MT
More news
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 550 M - -
Net Debt 2021 11 241 M - -
P/E ratio 2021 33,8x
Yield 2021 1,36%
Capitalization 222 B 222 B -
EV / Sales 2021 8,55x
EV / Sales 2022 8,28x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 244,15 $
Average target price 241,90 $
Spread / Average Target -0,92%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY44.60%209 276
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
NOVARTIS AG1.10%207 246
ABBVIE INC.10.30%199 548